Asset Details
Do you wish to reserve the book?
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
Do you wish to request the book?
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
2022
Overview
Deregulation of the BCL-2 family interaction network ensures cancer resistance to apoptosis and is a major challenge to current treatments. Cancer cells commonly evade apoptosis through upregulation of the BCL-2 anti-apoptotic proteins; however, more resistant cancers also downregulate or inactivate pro-apoptotic proteins to suppress apoptosis. Here, we find that apoptosis resistance in a diverse panel of solid and hematological malignancies is mediated by both overexpression of BCL-XL and an unprimed apoptotic state, limiting direct and indirect activation mechanisms of pro-apoptotic BAX. Both survival mechanisms can be overcome by the combination of an orally bioavailable BAX activator, BTSA1.2 with Navitoclax. The combination demonstrates synergistic efficacy in apoptosis-resistant cancer cells, xenografts, and patient-derived tumors while sparing healthy tissues. Additionally, functional assays and genomic markers are identified to predict sensitive tumors to the combination treatment. These findings advance the understanding of apoptosis resistance mechanisms and demonstrate a novel therapeutic strategy for cancer treatment.
Deregulation of the BCL-2 family interactions ensures cancer resistance to apoptosis and is a major challenge to current treatments. Here the authors describe a novel therapeutic strategy to overcome two anti-apoptotic mechanisms for cancer therapy.
Publisher
Nature Publishing Group UK,Nature Portfolio
Subject
/ 13/106
/ 13/2
/ 49/1
/ 64/60
/ 96/2
/ Aniline Compounds - pharmacology
/ Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Apoptosis Regulatory Proteins - metabolism
/ bcl-2-Associated X Protein - genetics
/ bcl-2-Associated X Protein - metabolism
/ Humanities and Social Sciences
/ Humans
/ Science
